Nielsen-Kudsk Jens Erik
Kardiologisk Afdeling B, Skejby Sygehus, Aarhus Universitetshospital, DK-8200 Arhus N.
Ugeskr Laeger. 2003 Jul 14;165(29):2891-4.
Blockade of endothelin receptors is a new drug principle for the treatment of pulmonary arterial hypertension. Bosentan is a competitive blocker of endothelin receptors administered by the oral route. In clinical trials it has been shown to increase the functional capacity of patients with pulmonary arterial hypertension. This article describes the background, results of clinical trials, and practical guidelines for the use of bosentan in pulmonary arterial hypertension.
内皮素受体阻断是治疗肺动脉高压的一种新药理原则。波生坦是一种通过口服给药的内皮素受体竞争性阻断剂。在临床试验中，它已被证明可提高肺动脉高压患者的功能能力。本文描述了波生坦用于肺动脉高压治疗的背景、临床试验结果及实用指南。
